Literature DB >> 25519898

[Selective internal radiotherapy (SIRT) of liver tumors].

H Duan1, M Hoffmann.   

Abstract

METHODICAL INNOVATIONS: Selective internal radiotherapy (SIRT) is a safe and efficacious, minimally invasive procedure to treat primary and secondary unresectable liver tumors. For hepatocellular carcinoma (HCC), SIRT has proven to be a well-tolerated therapy option even in advanced stages of disease. STANDARD RADIOLOGICAL
METHODS: In cases of portal vein thrombosis SIRT is the alternative to transarterial chemoembolization (TACE). PERFORMANCE: The role of SIRT regarding downstaging and bridging to transplantation is promising and SIRT has also been shown to be highly effective and well-tolerated in metastastic liver disease. ACHIEVEMENTS: The results of prospective randomized trials are awaited to prove the efficiency and safety of SIRT described in numerous retrospective and prospective non-randomized studies. PRACTICAL RECOMMENDATIONS: The indications are established within the framework of a tumor board.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25519898     DOI: 10.1007/s00117-014-2708-5

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  24 in total

1.  Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.

Authors:  Suzanne Kosmider; Thean H Tan; Desmond Yip; Richard Dowling; Meir Lichtenstein; Peter Gibbs
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

Review 2.  Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction.

Authors:  Riad Salem; Kenneth G Thurston
Journal:  J Vasc Interv Radiol       Date:  2006-10       Impact factor: 3.464

3.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

4.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

5.  Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.

Authors:  Akshat Saxena; Terence C Chua; Lourens Bester; Adel Kokandi; David L Morris
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

6.  Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.

Authors:  Philipp M Paprottka; Ralf-T Hoffmann; Alexander Haug; Wieland H Sommer; Franziska Raessler; Christoph G Trumm; Gerwin P Schmidt; Nima Ashoori; Maximilian F Reiser; Tobias F Jakobs
Journal:  Cardiovasc Intervent Radiol       Date:  2011-08-17       Impact factor: 2.740

7.  Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors.

Authors:  T W Leung; W Y Lau; S K Ho; S C Ward; J H Chow; M S Chan; C Metreweli; P J Johnson; A K Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-11-01       Impact factor: 7.038

8.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

Authors:  Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem
Journal:  Am J Clin Oncol       Date:  2008-06       Impact factor: 2.339

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

View more
  1 in total

1.  Current strategies in interventional oncology of colorectal liver metastases.

Authors:  Tatjana Gruber-Rouh; Christian Marko; Axel Thalhammer; Nour-Eldin Nour-Eldin; Marcel Langenbach; Martin Beeres; Nagy N Naguib; Stephan Zangos; Thomas J Vogl
Journal:  Br J Radiol       Date:  2016-05-26       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.